Literature DB >> 22748158

Cytokeratin 7: a re-evaluation of the 'tried and true' in triple-negative breast cancers.

Simone M Davion1, Kalliopi P Siziopikou, Megan E Sullivan.   

Abstract

AIMS: Triple-negative breast cancers (TNBCs) are often poorly differentiated tumours that can present clinically as metastases of an unknown primary. Immunohistochemical panels are frequently used to determine the likelihood of a breast primary, but in this tumour subset cytokeratin (CK)7 may be the only positive finding. In this study we aimed to evaluate a commonly employed immunohistochemical panel using a large group of TNBCs (both basal-like and unclassified), and to analyse the CK7 staining patterns. METHODS AND
RESULTS: Tissue microarrays containing 138 TNBCs were stained with antibodies against CK7, CK20, gross cystic disease fluid protein 15 (GCDFP-15), and mammaglobin. CK5/6 staining was used to identify basal-like tumours. CK7 staining was notably heterogeneous, with 14.5% of all cases demonstrating ≤20% tumour cell staining. A greater proportion of basal-like TNBCs than of unclassified TNBCs showed focal staining. GCDFP-15 and mammaglobin were not expressed in the majority of TNBCs, and were less frequently positive in basal-like than in unclassified TNBCs.
CONCLUSION: TNBCs are commonly negative for most immunomarkers indicative of breast origin, with the exception of CK7. As about one in five TNBCs showed only focal CK7 positivity, use of this marker must be interpreted with caution, especially in small samples, so that the possibility of a breast primary is not overlooked.
© 2012 Blackwell Publishing Ltd.

Entities:  

Keywords:  GCDFP-15; basal-like; cytokeratin 20; cytokeratin 5/6; cytokeratin 7; invasive ductal carcinoma; mammaglobin; triple-negative; unknown primary

Mesh:

Substances:

Year:  2012        PMID: 22748158     DOI: 10.1111/j.1365-2559.2012.04253.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  5 in total

Review 1.  Triple negative breast cancer: the kiss of death.

Authors:  Adriana-Andreea Jitariu; Anca Maria Cîmpean; Domenico Ribatti; Marius Raica
Journal:  Oncotarget       Date:  2017-07-11

2.  Cytokeratin 7-negative and GATA binding protein 3-negative breast cancers: Clinicopathological features and prognostic significance.

Authors:  Shaolei Lu; Evgeny Yakirevich; Li Juan Wang; Murray B Resnick; Yihong Wang
Journal:  BMC Cancer       Date:  2019-11-12       Impact factor: 4.430

3.  Visfatin Enhances Breast Cancer Progression through CXCL1 Induction in Tumor-Associated Macrophages.

Authors:  Yen-Yun Wang; Huan-Da Chen; Steven Lo; Yuk-Kwan Chen; Yu-Ci Huang; Stephen Chu-Sung Hu; Ya-Ching Hsieh; Amos C Hung; Ming-Feng Hou; Shyng-Shiou F Yuan
Journal:  Cancers (Basel)       Date:  2020-11-26       Impact factor: 6.639

4.  Spatial protein heterogeneity analysis in frozen tissues to evaluate tumor heterogeneity.

Authors:  Anna Fomitcheva-Khartchenko; Maria Anna Rapsomaniki; Bettina Sobottka; Peter Schraml; Govind V Kaigala
Journal:  PLoS One       Date:  2021-11-19       Impact factor: 3.240

5.  An analogue of a kinase inhibitor exhibits subjective characteristics that contribute to its inhibitory activities as a potential anti-cancer candidate: insights through computational biomolecular modelling of UM-164 binding with lyn protein.

Authors:  Umar Ndagi; Maryam Abdullahi; Asmau N Hamza; Mahmoud E Soliman
Journal:  RSC Adv       Date:  2019-12-24       Impact factor: 4.036

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.